Pfizer and Eli Lilly’s nerve growth factor (NGF) inhibitor tanezumab has inched closer to becoming the first alternative to opioid analgesics for severe pain after hitting the mark in a phase 3 trial. Two subcutaneous doses of tanezumab—given eight weeks apart—met all the objectives in the trial in patients with osteoarthritis pain, significantly improving pain, […]
About Evgeniy Makarevich
This author has yet to write their bio.Meanwhile lets just say that we are proud Evgeniy Makarevich contributed a whooping 106 entries.
Entries by Evgeniy Makarevich
The European Federation of Pharmaceutical Industries and Associations (EFPIA) strongly welcomes the approval of their own initiative report on “A European One Health Action Plan against Antimicrobial Resistance” by the Environment, Public Health and Food Safety (ENVI) Committee of the European Parliament on the 20th June 2018. The Committee of the European Parliament appeals to […]
The European medicines Agency (EMA) is examining medicines containing valsartan supplied by one of the companies in China, after they have been detected by an impurity that potentially causes cancer, according to PharmaTimes. Chinese company Zhejiang Huahai was found N-nitrosodimethylamine (NDMA) in some batches of the active substance (API) valsartan, supplied to a number of […]